Day Traders Tag icon

×
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of Novo Nordisk A/S’ (NYSE:NVO) Wegovy (semaglutide 2.4 mg) label. The label update incorporates data showing that Wegovy, when added to the standard of care, can reduce heart failure-related symptoms and improve physical limitations and exercise function in people with obesity-related HFpEF, with or without type 2 diabetes. Also Read: Ozempic Maker Novo Nordisk Touts Encouraging Data From New Obesity Pill Showing Double Weight Loss Compared To Wegovy Heart failure affects at least 64 million people worldwide and is especially prevalent in obese and/or type 2 diabetes patients. Heart failure with preserved ejection fraction (HFpEF) is now the most ...


In The news